Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India · Delayed Price · Currency is INR 201.60
-5.00 (-2.42%)
Jun 1, 2026, 3:29 PM IST
Jagsonpal Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 430.82 | 553.61 | 224.63 | 267.21 | 188.55 |
Depreciation & Amortization | 94.44 | 81.31 | 16.63 | 11.75 | 15.26 |
Loss (Gain) From Sale of Assets | - | -233.59 | - | -3.59 | -0.85 |
Asset Writedown & Restructuring Costs | - | 1.75 | - | 28.09 | - |
Loss (Gain) From Sale of Investments | - | - | - | -1.48 | -11.36 |
Stock-Based Compensation | 28.05 | 68.04 | 133.1 | 87.65 | - |
Provision & Write-off of Bad Debts | - | - | 7.67 | 2.62 | 0.42 |
Other Operating Activities | -61.25 | 26.64 | -85.76 | -20.66 | -8.33 |
Change in Accounts Receivable | -40.15 | -22.25 | 91.54 | -55.56 | -29.55 |
Change in Inventory | 5.28 | 0.01 | 53.1 | 86.86 | -0.18 |
Change in Accounts Payable | 18.47 | 21.38 | -89.82 | -19.62 | -10.75 |
Change in Other Net Operating Assets | -7.54 | 56.1 | 0.57 | 83.28 | -74.07 |
Operating Cash Flow | 468.12 | 553 | 351.66 | 466.55 | 69.14 |
Operating Cash Flow Growth | -15.35% | 57.25% | -24.63% | 574.79% | -75.50% |
Capital Expenditures | -1.48 | -3.48 | -2.48 | -3.18 | -10.49 |
Sale of Property, Plant & Equipment | - | 357.18 | - | 12.96 | 5.81 |
Cash Acquisitions | -12 | -936.57 | - | - | - |
Investment in Securities | -444.38 | 53 | -316.67 | -620.77 | -268.57 |
Other Investing Activities | 101.37 | 78.4 | 73.67 | 34.28 | 15.46 |
Investing Cash Flow | -356.49 | -451.47 | -245.48 | -576.71 | -257.79 |
Long-Term Debt Repaid | -12.21 | -9.02 | -6.33 | -0.44 | -67.88 |
Total Debt Repaid | -12.21 | -9.02 | -6.33 | -0.44 | -67.88 |
Net Debt Issued (Repaid) | -12.21 | -9.02 | -6.33 | -0.44 | -67.88 |
Issuance of Common Stock | 66.29 | 33.91 | 56.35 | - | - |
Common Dividends Paid | -166.58 | -132.29 | -130.99 | - | -104.79 |
Other Financing Activities | -8.99 | -9.58 | -8.14 | -4.13 | -2.85 |
Financing Cash Flow | -121.49 | -116.98 | -89.11 | -4.57 | -175.52 |
Net Cash Flow | -9.86 | -15.45 | 17.07 | -114.73 | -364.17 |
Free Cash Flow | 466.64 | 549.52 | 349.18 | 463.37 | 58.65 |
Free Cash Flow Growth | -15.08% | 57.37% | -24.64% | 690.06% | -78.87% |
Free Cash Flow Margin | 16.25% | 20.45% | 16.73% | 19.57% | 2.70% |
Free Cash Flow Per Share | 6.83 | 8.16 | 5.27 | 7.08 | 0.90 |
Cash Interest Paid | 8.99 | 8.58 | 7.77 | - | 2.61 |
Cash Income Tax Paid | 118.98 | 81.43 | 85.13 | 72.76 | 68.73 |
Levered Free Cash Flow | 397.7 | 638.24 | 197.59 | 425.62 | 49.28 |
Unlevered Free Cash Flow | 404.13 | 643.61 | 202.44 | 427.36 | 50.92 |
Change in Working Capital | -23.94 | 55.24 | 55.39 | 94.96 | -114.55 |